Variability in expression of homeobox genes (HOXA9) and (HOXA7) in acute myeloid leukemia patients

IF 3.2 4区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Current Research in Translational Medicine Pub Date : 2025-03-04 DOI:10.1016/j.retram.2025.103503

Zainab Tallima , Dalia Ibraheem , Manal Wilson , Sally Elfishawi

{"title":"Variability in expression of homeobox genes (HOXA9) and (HOXA7) in acute myeloid leukemia patients","authors":"Zainab Tallima , Dalia Ibraheem , Manal Wilson , Sally Elfishawi","doi":"10.1016/j.retram.2025.103503","DOIUrl":null,"url":null,"abstract":"<div><div>The strong association between NPM1 mutation and increased expression levels of HOXA7 and HOXA9 implies that HOXA genes may be utilized as targeted treatment markers in NPM1-mutated patients. We examined HOXA7 and HOXA9 gene expression in acute myeloid leukemia (AML) patients with nucleophosmin1 (NPM1) mutation. This study included 91 cases of AML and 23 samples of matched healthy controls. HOXA7 and HOXA9 gene expression was analyzed using real-time PCR with SYBR Green dye. All cases were subjected to NPM1 mutation detection. Both HOXA7 and HOXA9 gene expressions were significantly correlated with age, with adult patients exhibiting substantially higher gene expression than pediatric patients (<em>p</em> < 0.01). Both HOXA7 and HOXA9 high gene expressions were significantly associated with NPM1 mutation (<em>p</em> = 0.032 and <em>p</em> = 0.001, respectively). Adult patients with AML demonstrated a higher level of HOXA9 expression, which has a negative impact on the disease-free survival of NPM1-mutated patients (<em>p</em> = 0.055). Therefore, targeting the HOXA9 pathway presents a highly plausible treatment option for NPM1-mutated adult AML patients.</div></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"73 2","pages":"Article 103503"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452318625000121","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

The strong association between NPM1 mutation and increased expression levels of HOXA7 and HOXA9 implies that HOXA genes may be utilized as targeted treatment markers in NPM1-mutated patients. We examined HOXA7 and HOXA9 gene expression in acute myeloid leukemia (AML) patients with nucleophosmin1 (NPM1) mutation. This study included 91 cases of AML and 23 samples of matched healthy controls. HOXA7 and HOXA9 gene expression was analyzed using real-time PCR with SYBR Green dye. All cases were subjected to NPM1 mutation detection. Both HOXA7 and HOXA9 gene expressions were significantly correlated with age, with adult patients exhibiting substantially higher gene expression than pediatric patients (p < 0.01). Both HOXA7 and HOXA9 high gene expressions were significantly associated with NPM1 mutation (p = 0.032 and p = 0.001, respectively). Adult patients with AML demonstrated a higher level of HOXA9 expression, which has a negative impact on the disease-free survival of NPM1-mutated patients (p = 0.055). Therefore, targeting the HOXA9 pathway presents a highly plausible treatment option for NPM1-mutated adult AML patients.

查看原文本刊更多论文

同源盒基因（HOXA9）和（HOXA7）在急性髓系白血病患者中的表达变异性

NPM1突变与HOXA7和HOXA9表达水平升高之间的强相关性表明，HOXA基因可能被用作NPM1突变患者的靶向治疗标记物。我们检测了HOXA7和HOXA9基因在核磷蛋白1 （NPM1）突变的急性髓性白血病（AML）患者中的表达。本研究包括91例AML病例和23例匹配的健康对照样本。用SYBR绿染料实时荧光定量PCR检测HOXA7和HOXA9基因的表达。所有病例均进行NPM1突变检测。HOXA7和HOXA9基因表达均与年龄显著相关，成人患者的基因表达明显高于儿童患者(p <；0.01)。HOXA7和HOXA9基因高表达与NPM1突变显著相关（p = 0.032和p = 0.001）。成年AML患者表现出更高水平的HOXA9表达，这对npm1突变患者的无病生存有负面影响（p = 0.055）。因此，靶向HOXA9通路为npm1突变的成人AML患者提供了一种高度可信的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Research in Translational Medicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

7.00

自引率

4.90%

发文量

审稿时长

45 days

期刊介绍： Current Research in Translational Medicine is a peer-reviewed journal, publishing worldwide clinical and basic research in the field of hematology, immunology, infectiology, hematopoietic cell transplantation, and cellular and gene therapy. The journal considers for publication English-language editorials, original articles, reviews, and short reports including case-reports. Contributions are intended to draw attention to experimental medicine and translational research. Current Research in Translational Medicine periodically publishes thematic issues and is indexed in all major international databases (2017 Impact Factor is 1.9). Core areas covered in Current Research in Translational Medicine are: Hematology, Immunology, Infectiology, Hematopoietic, Cell Transplantation, Cellular and Gene Therapy.